Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
rituximab (rituxan) (1 trial)
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (Phase 3)
Granulomatosis with Polyangiitis (Phase 3)
Microscopic Polyangiitis (Phase 3)
Systemic Vasculitis (Phase 3)
Vasculitis (Phase 3)
Trials (1 total)
Trial APIs (1 total)